STOCK TITAN

PepGen Inc - PEPG STOCK NEWS

Welcome to our dedicated news page for PepGen (Ticker: PEPG), a resource for investors and traders seeking the latest updates and insights on PepGen.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PepGen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PepGen's position in the market.

Rhea-AI Summary
PepGen Inc. receives Fast Track designation from the FDA for PGN-EDODM1, a potential therapy for myotonic dystrophy type 1. The company aims to address the root cause of the disease and improve outcomes for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
Rhea-AI Summary
PepGen Inc. announced the pricing of an underwritten offering of 7,530,000 shares of its common stock at a price to the public of $10.635 per share, with expected gross proceeds of approximately $80.1 million. The offering aims to support the company's advancement of oligonucleotide therapies for severe neuromuscular and neurological diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.63%
Tags
offering
-
Rhea-AI Summary
PepGen Inc. (Nasdaq: PEPG) has announced the appointment of Mary Beth DeLena as General Counsel and Secretary. DeLena brings over 20 years of experience advising global life science companies, with extensive expertise in business development, finance, securities, corporate governance, employment, and commercial law. Her previous roles at Alnylam Pharmaceuticals and Praecis Pharmaceuticals, as well as her legal career at Skadden, Arps, Slate, Meagher & Flom LLP, demonstrate her significant contributions to the growth and success of these companies. Mary Beth's appointment is expected to play a crucial role in advancing PepGen's goal of delivering next-generation oligonucleotide therapies for severe neuromuscular and neurological diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.17%
Tags
none
Rhea-AI Summary
PepGen Inc. (Nasdaq: PEPG) announced the dosing of the first patient in its CONNECT1-EDO51 Phase 2 trial, evaluating PGN-EDO51 for the treatment of Duchenne muscular dystrophy (DMD) patients. Preliminary data from the 5 mg/kg PGN-EDO51 dose level is expected mid-2024, with Phase 1 results showing peak exon 51 skipping of 3.8% and 100% of subjects demonstrating exon skipping. The company aims to develop therapies to improve the lives of people living with DMD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
clinical trial
-
Rhea-AI Summary
PepGen Inc. (Nasdaq: PEPG) announces dosing of the first patient in its Phase 1 clinical trial, FREEDOM-DM1, to evaluate PGN-EDODM1 for the treatment of DM1. The company anticipates proof-of-concept data in 2024, including safety, transcript splicing, and clinical outcome measures at the 5 mg/kg dose level. The trial is intended to enroll approximately 24 adult patients with DM1 to evaluate safety, tolerability, and clinical outcomes impacted in DM1.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.03%
Tags
clinical trial
-
Rhea-AI Summary
PepGen Inc. (Nasdaq: PEPG) appoints Howard Mayer, M.D. to its Board of Directors. Dr. Mayer brings extensive clinical development and regulatory experience to the company, enhancing its mission to revolutionize genetic therapies for severe neuromuscular and neurological diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.4%
Tags
management
Rhea-AI Summary
PepGen Inc. (Nasdaq: PEPG) reported Q3 2023 financial results, highlighting progress in clinical trials for neuromuscular and neurological diseases. Recent developments include FDA clearance for FREEDOM-DM1 study, Orphan Drug Designation, and CONNECT1-EDO51 advancements. The company ended Q3 2023 with $129.5 million in cash and cash equivalents, expected to fund operations into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.4%
Tags
earnings
-
Rhea-AI Summary
PepGen Inc. receives FDA clearance to initiate the FREEDOM-DM1 Phase 1 study of PGN-EDODM1 in patients with myotonic dystrophy type 1 (DM1) in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.22%
Tags
clinical trial
-
Rhea-AI Summary
PepGen Inc. will be presenting at the 28th Annual Congress of the World Muscle Society, showcasing their advancements in oligonucleotide therapies for neuromuscular diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.97%
Tags
conferences
Rhea-AI Summary
PepGen receives FDA orphan drug designation for PGN-EDODM1 to treat myotonic dystrophy type 1
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.64%
Tags
clinical trial
PepGen Inc

Nasdaq:PEPG

PEPG Rankings

PEPG Stock Data

431.91M
12.07M
0.05%
79.13%
1.2%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Boston